All New Products Listed Chronologically

Cat.No. Product Name Information Added
S3412 CYM50308 CYM50308 (ML248) is a potent and selective S1P4 receptor agonist with an EC50 of 56 nM. Oct 21 2021
E0023 5,7-Dihydroxychromone

5,7-Dihydroxychromone (DHC), a natural antioxidant extracted from plants, is a potent activator of Nrf2/ARE signal. 5,7-dihydroxychromone also is a potent activator of PPARγ and LXRα. 5,7-Dihydroxychromone may contributes to regulate blood glucose levels and shows anti-diabetic property.

Oct 20 2021
S9898 Proxalutamide (GT0918)

Proxalutamide (GT0918) is a second-generation androgen receptor antagonist that binds to the ligand-binding domain of AR with an IC50 of 32 nM in the AR competive binding assays.

Oct 20 2021
E0124 Chelerythrine

Chelerythrine (Toddaline, Broussonpapyrine) is a potent, selective antagonist of PKC with an IC50 of 0.66 μM. Chelerythrine also inhibits the BclXL-Bak BH3 peptide binding with an IC50 of 1.5 μM. Chelerythrine shows antitumor, antidiabetic and anti-inflammatory activity.

Oct 20 2021
S3462 PS210 PS210 is a potent activator of PDK1 that binds to the PIF-pocket and allosterically modulates the active site of PDK1. Oct 18 2021
E0073 CL-82198 CL-82198 is a selective, orally bioavailable MMP-13 inhibitor with an IC50 of 3.2 μM. Oct 18 2021
E0069 DFHBI DFHBI is a mimic of green fluorescent protein (GFP) fluorophore and binds to RNA aptamers. DFHBI can be used for imaging RNA in living cells. Oct 18 2021
E0102 I-191 I-191 is a potent PAR2 antagonist that inhibits multiple PAR2-induced signaling pathways and functional responses. I-191 also inhibits ERK1/2 phosphorylation, RhoA activation, and inhibition of forskolin-stimulated cAMP accumulation induced by micromolar concentrations of biased ligand GB88. Oct 18 2021
E0072 Indirubin-3′-oxime Indirubin-3′-oxime (IDR3O, I3O) is an indirubin analogue that shows favorable inhibitory activity targeting GSK-3β and CDKs. Indirubin-3′-oxime also inhibits JNKs with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM for JNK1, JNK2, and JNK3, respectively. Indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity. Oct 18 2021
E0112 INH154 INH154 is a potent inhibitor of Nek2 and Hec1 binding. NH154 binds to Hec1, thus blocking Hec1 phosphorylation by NEK2, and kills cancer cells at the nanomolar range. Oct 18 2021
E0119 Iptacopan (LNP023) Hydrochloride Iptacopan (LNP023) Hydrochloride is a first-in-class, orally administered, potent and highly selective factor B inhibitor with an IC50 of 12 nM and a Kd value of 7.9 nM. Iptacopan exhibits excellent selectivity over other proteases affording IC50s of >30 μM across a panel of 41 human proteases. Oct 18 2021
E0092 KEA1-97 KEA1-97 selectively modulates certain functions of thioredoxin (TXN) through protein interactions with caspase 3 without affecting its catalytic activity. Oct 18 2021
E0108 LQZ-7I LQZ-7I is a novel selectively inhibitor of survivin dimerization with IC50s of 4.8 µM and 3.1 µM in prostate cancer cell lines PC-3 and C4-2, respectively. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors. Oct 18 2021
E0052 Merafloxacin Merafloxacin (CI-934) is a fluoroquinolone antibacterial thats inhibit -1 frameshifting efficiency of SARS-CoV-2 and other betacoronaviruses. Oct 18 2021
E0116 PF-06446846 hydrochloride PF-06446846 (PF846) Hydrochloride is an orally bioavailable and specific inhibitor of PCSK9 with an IC50 of 0.3 µM in Huh7 cells. Oct 18 2021
S0837 HJC0197 HJC0197 is a selective Epac 1/2 dual antagonists with an IC50 of 5.9 μM for Epac2. Oct 18 2021
E0049 Pizuglanstat (TAS-205) Pizuglanstat (TAS-205) is a highly selective hematopoietic prostaglandin D synthase (HPGDS) inhibitor with an IC50 of 55.8 nM. Oct 18 2021
E0050 Seralutinib (GB002) Seralutinib (PK10571, GB002) is a novel PDGFR kinase inhibitor with IC50s of 8 nM and 10 nM for PDGFRα and PDGFRβ in enzyme assays, respectively. Oct 18 2021
E0076 Simufilam dihydrochloride Simufilam (PTI-125) Dihydrochloride is a small molecule modulator that preferentially binds altered FLNA and restores its native conformation, restoring receptor and synaptic activities and reducing its α7nAChR/TLR4 associations and downstream pathologies. Oct 18 2021
E0041 Tolebrutinib (SAR442168) Tolebrutinib (SAR442168, PRN2246, BTKi'168, BTKi('168)) is an oral, CNS-penetrant, irreversible inhibitor of Bruton's tyrosine kinase (BTK) with IC50s of 0.4 nM and 0.7 nM in Ramos B cells and in HMC microglia cells, respectively. Oct 18 2021
Page: